Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/763qfd/nitric_oxide) has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering.
This report Analyses the latest concepts of nitric oxide (NO) and the role it plays in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2014 and is projected to 2019 and 2024 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 34 companies involved in this area of which 8 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 15 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 25 tables and 26 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/763qfd/nitric_oxide
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 



